Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more
Neuphoria Therapeutics Inc (NEUP) - Total Assets
Latest total assets as of December 2025: $36.60 Million USD
Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) holds total assets worth $36.60 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neuphoria Therapeutics Inc - Total Assets Trend (1999–2025)
This chart illustrates how Neuphoria Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neuphoria Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Neuphoria Therapeutics Inc's total assets of $36.60 Million consist of 52.6% current assets and 47.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.7% |
| Accounts Receivable | $11.95 Million | 27.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.30 Million | 16.8% |
| Goodwill | $13.13 Million | 30.2% |
Asset Composition Trend (1999–2025)
This chart illustrates how Neuphoria Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuphoria Therapeutics Inc's current assets represent 52.6% of total assets in 2025, a decrease from 100.0% in 1999.
- Cash Position: Cash and equivalents constituted 49.7% of total assets in 2025, up from 40.4% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 30.2% of total assets.
Neuphoria Therapeutics Inc Competitors by Total Assets
Key competitors of Neuphoria Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Neuphoria Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Neuphoria Therapeutics Inc generates 0.55x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Neuphoria Therapeutics Inc is currently not profitable relative to its asset base.
Neuphoria Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.04 | 2.06 | 0.74 |
| Quick Ratio | 9.04 | 2.06 | 0.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $20.80 Million | $ 2.27 Million | $ -1.85 Million |
Neuphoria Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Neuphoria Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.78 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 57.1% |
| Total Assets | $43.44 Million |
| Market Capitalization | $19.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Neuphoria Therapeutics Inc's assets below their book value (0.44 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Neuphoria Therapeutics Inc's assets grew by 57.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuphoria Therapeutics Inc (1999–2025)
The table below shows the annual total assets of Neuphoria Therapeutics Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $43.44 Million | +57.11% |
| 2024-06-30 | $27.65 Million | +42.57% |
| 2023-06-30 | $19.39 Million | -56.83% |
| 2022-06-30 | $44.93 Million | +10.20% |
| 2021-06-30 | $40.77 Million | +72.17% |
| 2020-06-30 | $23.68 Million | -36.99% |
| 2019-06-30 | $37.58 Million | -21.38% |
| 2018-06-30 | $47.80 Million | -26.02% |
| 2017-06-30 | $64.61 Million | -1.70% |
| 2016-06-30 | $65.72 Million | +23.95% |
| 2015-06-30 | $53.02 Million | -13.44% |
| 2014-06-30 | $61.25 Million | +25.20% |
| 2013-06-30 | $48.93 Million | +53.71% |
| 2012-06-30 | $31.83 Million | -13.19% |
| 2011-06-30 | $36.67 Million | +36.91% |
| 2010-06-30 | $26.78 Million | +34.22% |
| 2009-06-30 | $19.95 Million | -26.34% |
| 2008-06-30 | $27.09 Million | +3.62% |
| 2007-06-30 | $26.14 Million | +78.69% |
| 2006-06-30 | $14.63 Million | +12.53% |
| 2005-06-30 | $13.00 Million | +24.28% |
| 2004-06-30 | $10.46 Million | +23.50% |
| 2003-06-30 | $8.47 Million | -5.01% |
| 2002-06-30 | $8.92 Million | +61.36% |
| 2001-06-30 | $5.53 Million | +74.38% |
| 2000-06-30 | $3.17 Million | +2128.83% |
| 1999-06-30 | $142.19K | -- |